ORIC
Oric Pharmaceuticals, Inc.
$8.27
+5.75%
$856.1M
No data for this timeframe.
Vol
Market Cap$856.1M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (91%)
Inst. Holders50 funds
Inst. Value$491.0M
Inst. Activity12 buys / 6 sells
Reddit Sentiment50° Neutral
SEC Reports2
Press Releases1
Recent Activity
Jun 11, 2026
SEC
Four mega-passive institutional investors (Vanguard, BlackRock, State Street, Morgan Stanley) collectively added $63.2M
INST-CLUSTER — Impact 3/10
Jun 5, 2026
other
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- OR
May 4, 2026
SEC
ORIC Pharmaceuticals reported Q1 2026 net loss of $35.8M ($0.34/share), missing consensus estimates of $0.31/share by 9.
8-K — Impact 4/10
Apr 3, 2026
Press
ORIC Pharmaceuticals announced the grant of stock options and restricted stock units to a new non-executive employee as
Impact 2/10
Feb 24, 2026
Insider
Piscitelli Dominic acquired via exercise 52,000 shares
Chief Financial Officer @ $4.36 ($226.7K)
Inst.
MORGAN STANLEY — ADD
1,682,523 shares ($21.3M)
Inst.
Woodline Partners LP — DOUBLED
1,247,515 shares ($15.8M)
Price Targets
$20.29
+145.3% upside
Strong Buy
Current $8.27
Low $14.00
Median $21.00
High $25.00
14 analysts
$14.00
$25.00
Analyst Ratings
9Strong Buy
11Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 8, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 15, 2026 | Goldman Sachs | UPGRADE | Buy |
| May 5, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| Apr 2, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Apr 1, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.36 ▼ -0.6% | $-0.40 — $-0.30 | 23% YoY | 15 |
| Next Q | $-0.37 | $-0.45 — $-0.30 | -12% YoY | 15 |
| Current FY | $-1.46 | $-1.66 — $-1.30 | 1% YoY | 15 |
| Next FY | $-1.57 ▼ -1.6% | $-1.86 — $-1.20 | -8% YoY | 13 |
Latest Reports
NEUTRAL
INST-CLUSTER
3/10
Four mega-passive institutional investors (Vanguard, BlackRock, State Street, Morgan Stanley) collectively added $63.2M
Jun 11, 2026
MIXED
8-K
4/10
ORIC Pharmaceuticals reported Q1 2026 net loss of $35.8M ($0.34/share), missing consensus estimates of $0.31/share by 9.
May 4, 2026
NEUTRAL
Press
2/10
ORIC Pharmaceuticals announced the grant of stock options and restricted stock units to a new non-executive employee as
Apr 3, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $75.8M | ADD |
| ALKEON CAPITAL MANAGEMENT LLC | $57.1M | — |
| STATE STREET CORP | $46.9M | ADD |
| VANGUARD CAPITAL MANAGEMENT LLC | $46.7M | — |
| FMR LLC | $30.8M | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Feb 24, 2026 | Piscitelli Dominic | M | $226.7K |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
50 institutional holders with $491.0M total value (38,779,191 shares) as of 2026-Q1. Top holders: BlackRock,, ALKEON, STATE. Net buying activity: 12 institutions added/increased vs 6 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 5,984,552 | $75.8M | 15.4% | ADD +29.4% |
| 2 | ALKEON CAPITAL MANAGEMENT LLC | 4,504,096 | $57.1M | 11.6% | — |
| 3 | STATE STREET CORP | 3,702,196 | $46.9M | 9.6% | ADD +77.1% |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 3,687,007 | $46.7M | 9.5% | — |
| 5 | FMR LLC | 2,434,080 | $30.8M | 6.3% | — |
| 6 | CITADEL ADVISORS LLC | 2,422,741 | $30.7M | 6.3% | — |
| 7 | MORGAN STANLEY | 1,682,523 | $21.3M | 4.3% | ADD +40.9% |
| 8 | GOLDMAN SACHS GROUP INC | 1,475,712 | $18.7M | 3.8% | — |
| 9 | DIMENSIONAL FUND ADVISORS LP | 1,471,290 | $18.6M | 3.8% | ADD +54.6% |
| 10 | FRANKLIN RESOURCES INC | 1,452,835 | $18.4M | 3.7% | — |
| 11 | Woodline Partners LP | 1,247,515 | $15.8M | 3.2% | DOUBLED +406.0% |
| 12 | ROYCE & ASSOCIATES LP | 1,207,223 | $15.3M | 3.1% | DOUBLED +521.2% |
| 13 | BANK OF AMERICA CORP /DE/ | 1,043,159 | $13.2M | 2.7% | DOUBLED +105.5% |
| 14 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 605,037 | $7.7M | 1.6% | ADD +57.7% |
| 15 | VANGUARD PORTFOLIO MANAGEMENT LLC | 570,691 | $7.2M | 1.5% | — |
| 16 | Polar Capital Holdings Plc | 539,377 | $6.8M | 1.4% | — |
| 17 | BALYASNY ASSET MANAGEMENT L.P. | 523,790 | $6.6M | 1.4% | TRIM -44.9% |
| 18 | Connor, Clark & Lunn Investment Management Ltd. | 522,061 | $6.6M | 1.3% | ADD +48.8% |
| 19 | VANGUARD FIDUCIARY TRUST CO | 507,294 | $6.4M | 1.3% | — |
| 20 | VICTORY CAPITAL MANAGEMENT INC | 405,280 | $5.1M | 1.0% | DOUBLED +151.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 1,194,073 | 1,682,523 | +40.9% | $21.3M | 2026-Q1 |
| Woodline Partners LP | DOUBLED | 246,534 | 1,247,515 | +406.0% | $15.8M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 507,510 | 1,043,159 | +105.5% | $13.2M | 2026-Q1 |
| BALYASNY ASSET MANAGEMENT L.P. | TRIM | 950,214 | 523,790 | -44.9% | $6.6M | 2026-Q1 |
| Connor, Clark & Lunn Investment Management Ltd. | ADD | 350,884 | 522,061 | +48.8% | $6.6M | 2026-Q1 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | TRIM | 549,000 | 344,315 | -37.3% | $4.4M | 2026-Q1 |
| Russell Investments Group, Ltd. | ADD | 207,037 | 263,059 | +27.1% | $3.3M | 2026-Q1 |
| TD ASSET MANAGEMENT INC | ADD | 169,830 | 258,602 | +52.3% | $3.3M | 2026-Q1 |
| ExodusPoint Capital Management, LP | ADD | 108,835 | 186,145 | +71.0% | $2.4M | 2026-Q1 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | ADD | 128,649 | 182,139 | +41.6% | $2.3M | 2026-Q1 |
| Rafferty Asset Management, LLC | TRIM | 177,179 | 115,480 | -34.8% | $1.5M | 2026-Q1 |
| STATE OF WISCONSIN INVESTMENT BOARD | TRIM | 124,345 | 38,295 | -69.2% | $485.2K | 2026-Q1 |
| STIFEL FINANCIAL CORP | ADD | 13,490 | 23,899 | +77.2% | $302.8K | 2026-Q1 |
| Brevan Howard Capital Management LP | NEAR_EXIT | 89,532 | 19,709 | -78.0% | $249.7K | 2026-Q1 |
| PRICE T ROWE ASSOCIATES INC /MD/ | ADD | 3,295,122 | 5,387,783 | +63.5% | $68.3K | 2026-Q1 |
| NISA INVESTMENT ADVISORS, LLC | ADD | 2,410 | 3,310 | +37.3% | $41.9K | 2026-Q1 |
| BNP Paribas Asset Management Holding S.A. | ADD | 647 | 1,114 | +72.2% | $14.1K | 2026-Q1 |
| Point72 Asset Management, L.P. | EXIT | 2,923,077 | 0 | -100.0% | $0.00 | 2026-Q1 |
| STATE STREET CORP | ADD | 2,403,939 | 4,258,397 | +77.1% | $34.8M | 2025-Q4 |
| DIMENSIONAL FUND ADVISORS LP | ADD | 793,871 | 1,227,230 | +54.6% | $10.0M | 2025-Q4 |
| MORGAN STANLEY | ADD | 745,528 | 1,194,073 | +60.2% | $9.8M | 2025-Q4 |
| BALYASNY ASSET MANAGEMENT L.P. | TRIM | 1,519,314 | 950,214 | -37.5% | $7.8M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 14,500 | 572,724 | +3849.8% | $4.7M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 103,450 | 507,510 | +390.6% | $4.2M | 2025-Q4 |
| Connor, Clark & Lunn Investment Management Ltd. | DOUBLED | 16,437 | 350,884 | +2034.7% | $2.9M | 2025-Q4 |
1 unique insiders with 1 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Feb 24, 2026 | Piscitelli Dominic | Chief Financial Officer | EXERCISE | 52,000 | $4.36 | $226.7K |
2 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 1 neutral. Avg impact: 3.5/10.
Current analyst consensus: Strong Buy (91% buy). Based on 22 analysts: 9 strong buy, 11 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$20.29 mean target
+145.3% upside
Strong Buy (1.24)
$14.00 Low
$25.00 High
| Metric | Value |
|---|---|
| Current Price | $8.27 |
| Target Low | $14.00 |
| Target Mean | $20.29 |
| Target Median | $21.00 |
| Target High | $25.00 |
| # Analysts | 14 |
| Recommendation | Strong Buy (1.24) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.36 | $-0.40 | $-0.30 | 23.4% | -0.6% | 2↑ 7↓ | $0.0B | 0.0% | 15 |
| Next Q 2026-09-30 |
$-0.37 | $-0.45 | $-0.30 | -11.8% | +0.2% | 3↑ 6↓ | $0.0B | 0.0% | 15 |
| Current FY 2026-12-31 |
$-1.46 | $-1.66 | $-1.30 | 0.9% | -0.2% | 2↑ 8↓ | $0.0B | 0.0% | 15 |
| Next FY 2027-12-31 |
$-1.57 | $-1.86 | $-1.20 | -8.0% | -1.6% | 4↑ 4↓ | $0.0B | 0.0% | 13 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.360 | |
| 7d ago | $-0.358 | -0.002 |
| 30d ago | $-0.358 | -0.002 |
| 60d ago | $-0.343 | -0.018 |
| 90d ago | $-0.343 | -0.017 |
5 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 8, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 15, 2026 | Goldman Sachs | UPGRADE | — | Buy |
| May 5, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Apr 2, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 1, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| Mar 13, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Feb 24, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Feb 24, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 24, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Jan 13, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Jan 7, 2026 | Piper Sandler | INITIATE | — | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 9 | 11 | 2 | 0 | 0 | 91% | |
| May 1, 2026 | 9 | 10 | 2 | 0 | 0 | 90% | |
| Apr 1, 2026 | 9 | 10 | 2 | 0 | 0 | 90% | |
| Mar 1, 2026 | 9 | 10 | 2 | 0 | 0 | 90% | |
| Feb 1, 2026 | 9 | 10 | 2 | 0 | 0 | 90% | |
| Jan 1, 2026 | 9 | 9 | 2 | 0 | 0 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
1 mentions
0 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 1, 2026 | 1 | 44° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
01 APIRL 2026 , WHAT ARE THE BIGGEST WINNERS ?
▲ 1
💬 1
⚡ 0.5
Jun 5, 2026
other
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 05, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical
Jun 2, 2026
short_volume
Short Volume: ORIC — 57.9% short (1.2M / 2.1M)
Short: 1,197,005 | Exempt: 19,435 | TRF Vol: 2,067,511 | Short Ratio: 57.9% | Off-exchange volume (dark pool + OTC)
May 27, 2026
other
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
<p align="justify">SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical
May 11, 2026
earnings_calendar
ORIC Q1 2026 Earnings Scheduled — 2026-05-11
May 6, 2026
short_volume
Short Volume: ORIC — 56.3% short (0.3M / 0.6M)
Short: 324,204 | Exempt: 0 | TRF Vol: 575,765 | Short Ratio: 56.3% | Off-exchange volume (dark pool + OTC)
May 4, 2026
earnings
ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates
<p align="center"><em>Announced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 global registrational trial i
May 4, 2026
earnings_calendar
ORIC Q1 2026 Earnings Scheduled — 2026-05-04
May 1, 2026
other
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 01, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical
May 1, 2026
short_interest
FTD: ORIC — 94,102 shares ($0.9M) failed to deliver
Settlement: 20260501, Price: $9.88, FTD Value: $929,727.76, ORIC PHARMACEUTICALS INC COM
Apr 22, 2026
short_volume
Short Volume: ORIC — 66.1% short (0.5M / 0.7M)
Short: 473,296 | Exempt: 0 | TRF Vol: 715,752 | Short Ratio: 66.1% | Off-exchange volume (dark pool + OTC)
Apr 17, 2026
routine
ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting
<p align="justify">SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 17, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinic
Apr 10, 2026
short_volume
Short Volume: ORIC — 62.9% short (0.6M / 1.0M)
Short: 621,200 | Exempt: 0 | TRF Vol: 987,694 | Short Ratio: 62.9% | Off-exchange volume (dark pool + OTC)
Apr 6, 2026
short_interest
FTD: ORIC — 141,800 shares ($1.3M) failed to deliver
Settlement: 20260406, Price: $8.89, FTD Value: $1,260,602, ORIC PHARMACEUTICALS INC COM
Apr 3, 2026
regulatory
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 03, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinica
Apr 2, 2026
short_interest
FTD: ORIC — 300,200 shares ($2.2M) failed to deliver
Settlement: 20260402, Price: $7.48, FTD Value: $2,245,496, ORIC PHARMACEUTICALS INC COM